Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

In this study, researchers developed a dissolvable microneedle patch combining HA-TEMPO and Portulaca oleracea L.-derived nanoparticles, which effectively reduced oxidative stress and inflammation in an atopic dermatitis model while restoring immune balance, suggesting a promising treatment strategy.

In this double-blind randomized controlled trial, both rosemary extract lotion and 2% ketoconazole lotion were effective for treating scalp seborrheic dermatitis, but rosemary lotion reduced itching more significantly, while ketoconazole was more effective in reducing dandruff.

This source discusses the potential of topical JAK inhibitors, like tofacitinib, as effective treatments for autoimmune skin diseases, emphasizing their superior safety profile and minimal adverse effects compared to conventional systemic therapies.

In this report, a 61-year-old woman with vitiligo showed significant improvement after tofacitinib treatment but developed lung adenocarcinoma, highlighting potential cancer risks associated with JAK inhibitors.

This study found that laboratory and African spiny mice have distinct spatiotemporal patterns in wound-induced hair neogenesis, with the Twist1 pathway playing a central role in epidermal-dermal interactions for hair primordia formation.

This article discusses the underutilization of spironolactone in dermatology for conditions like acne, highlighting its potential benefits and good safety profile, but reports no new clinical findings.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that vitamin D levels in children with autoimmune alopecia were often below optimal, but did not suggest a need for extra vitamin D screening beyond standard practices.

This study in Tehran found that, after adjusting for confounders, women with PCOS had no different risk of non-pregnancy after assisted reproductive treatment compared to women without PCOS.

This review discusses current advancements in mesenchymal stem cell-based therapies for skin repair and rejuvenation, focusing on therapeutic strategies, particularly highlighting the potential of neonatal and placenta-derived MSCs, and reports no new clinical results.

This review outlines recent advancements in understanding how micro-RNAs (miRNAs) influence hair regeneration, highlighting their role in stimulating hair growth and potential therapeutic approaches, while also addressing the challenges of clinical translation due to miRNAs' complex roles and delivery issues.

In this case report, a woman with ulcerative colitis experienced clinical deterioration during upadacitinib therapy, which improved after discontinuation, strongly suggesting drug hypersensitivity to the Janus kinase inhibitor as a potential cause for her symptoms.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

In this study, researchers used a mouse model to identify an adipocyte-to-fibroblast conversion pathway that promotes mast-cell recruitment and dermal fibrosis in atopic dermatitis, suggesting a potential therapeutic approach to block this process and reduce inflammation and fibrosis.

This study highlights that while advances in dermatology, such as biologics and JAK inhibitors, have improved treatments for conditions like atopic dermatitis and psoriasis, challenges remain, including issues with lasting efficacy and the need for more personalized therapies.

This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.

In this laboratory study, α-mangostin was found to significantly reduce melanin content and downregulate pigmentation-related genes in cultured skin and B16F10 cells, suggesting potential application as a natural whitening agent in sunscreen development.

In this case report, researchers describe a 44-year-old woman with refractory patch alopecia areata achieving complete hair regrowth using a multi-modal approach of systemic and topical cholecalciferol with microneedling, although systemic vitamin D repletion remains a significant confounder.

This study evaluated the efficacy and safety of tofacitinib for treating severe alopecia areata in five patients, finding that three responded favorably with mild side effects, supporting its potential use based on existing research.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

This study found that inhibiting prolactin secretion during the telogen phase can reduce the number of activated secondary hair follicles and the width of hair bulbs.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

This study discusses the role of Janus kinase inhibitors in treating severe alopecia areata, highlighting their potential to personalize treatment and improve patient quality of life, while addressing concerns about disease relapse after stopping treatment and the safety of long-term use.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

In this phase I/II clinical trial, placenta-derived mesenchymal stem cell exosome therapy significantly improved hair density and diameter, and reduced hair loss in patients with androgenetic alopecia, though further large-scale studies are needed to confirm these results and investigate the underlying molecular mechanisms.

In this experimental study, laser irradiation significantly altered the gene expression of cytokines in cultured human T-cell lymphocytes, suggesting that such laser light may photobiomodulate cytokine production in vitro.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.